NEW YORK, Feb. 16, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Future Infectious Disease Nucleic Acid Testinghttp://www.reportlinker.com/p0773575/Future-Infectious-Disease-Nucleic-Acid-Testing.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory
This 360-page report presents an overview of the clinical significance and market needs for major infectious diseases, as well as extensive listings of companies developing and marketing molecular diagnostic technologies and products.
Contains 360 pages and 20 tables
Table of Contents2. Major Infectious Diseases
* AIDS
O Structure and Composition
O Classification
O AIDS Origins
O Animal Lentivirus Systems
O Virus Receptors
O HIV Infections in Humans
- Pathogenesis and Pathology
O CD4T Lymphocytes and Memory Cells
O Monocytes and Macrophages
O Lymphoid Organs
O Neural Cells
O Viral Coinfections
- Clinical Findings
O Plasma Viral Load
O Pediatric AIDS
- Neurologic Disease
- Opportunistic Infections
- Cancer
O Immunity
- Virus Isolation
- Serology
- Viral Nucleic Acid/Antigen Detection
O Epidemiology
- Worldwide Spread of AIDS
- United States
- Routes of Transmission
O DNA Probes- Overview- Quantitative PCR- In Situ PCR- Needed ImprovementsO Viral Load/Drug Resistance TestingO Genotype and Phenotype TestingO Blood Banking Considerations* AdenovirusO BackgroundO Diagnostic TestsO Vaccines and DrugsO Adeno-Associated Viruses (AAV)* Anthrax/Bacillus AnthracisO BackgroundO Diagnostic TestsO Vaccines and Drugs* BabesiosisO Background* BEA and Other Bartonella DiseasesO BackgroundO Diagnostic TestsO Vaccines and Drugs* Chagas DiseaseO Background* CampylobacterO BackgroundO Diagnostic Tests- Culture IdentificationO Vaccines and Drugs* ChlamydiaO Background- Chlamydia psittaci- Chlmaydia pneumoniae- Chlamydia trachomatisO Diagnostic TestsO Vaccines and Drugs* Creutzfeldt-Jakob's DiseaseO BackgroundO Blood TransmissionO Diagnostic Tests
O Major Commercial and Academic Players
- Bayer
- Disease Sciences/Bio Tec Global
- Imperial College School of Medicine
- Ortho-Clinical Diagnostics
- Pall
- ProMetic Life Sciences
- Proteome Sciences/Idexx
- Q-One Biotech
- Serono
- U.S. Agricultural Research Service
O Drugs
O Vaccines
* Cytomegalovirus
O Background
- Chorioretinitis
- Gastrointestinal
- Central Nervous System Disease
O Diagnostic Tests
O Vaccines and Drugs
* Ebola Virus
O Background
- Epidemiology
- Clinical Syndromes
O Diagnostic Tests
O Vaccines and Drugs
* EchoVirus
O Background
- Acute Aseptic Meningitisis
- Encephalitis
- Exanthems
- Respiratory Disease
- Myopericarditis
- Neonatal Infections
O Diagnostic Tests
O Vaccines and Drugs
* Encephalitis
O Background
O Diagnostic Tests
O Vaccines and Drugs
* EnterovirusesO BackgroundO Diagnostic Tests- Viral Isolation and Identification- Antibody TestsO Vaccines and Drugs* Epstein-Barr VirusO BackgroundO Diagnostic TestsO Vaccines and Drugs* GonorrheaO BackgroundO Diagnostic TestsO Vaccines and Drugs* HepatitisO Hepatitis AO Hepatitis B- Structure and Composition- ReplicationO Hepatitis CO Hepatitis D (Delta)O Hepatitis EO Hepatitis GO Hepatitis Infections PathologyO Clinical FindingsO Laboratory Tests- Hepatitis A- Hepatitis B- Hepatitis C- Hepatitis D- Hepatitis EO Virus-Host Immune ReactionsO Epidemiology- Hepatitis A- Hepatitis B- Hepatitis C- Hepatitis D (Delta)O Vaccines and Drugs
* Herpes Simplex Virus
O Background
O Diagnostic Tests
O Vaccines and Drugs
* Legionella
O Background
O Diagnostic Tests
O Vaccines and Drugs
* Lyme Disease
O Background
- Clinical Description
- Clinical Case Definition
- Laboratory Criteria for Diagnosis
- Case Classification
O Diagnostic Tests
O Vaccines and Drugs
* Malaria
* Mycoplasma
O Background
- Ureaplasma Urealyticum & Mycoplasma
Hominis
O Diagnostic Tests
O Vaccines and Drugs
* Papillomaviruses/HPV
O Background
- HPV in Cancer
- Cervical Neoplasm
O Diagnostic Tests
O Vaccines and Drugs
- Prevention
* Parvovirus B19
O Background
- Microbiology
- Epidemiology
- Clinical Syndromes
- Erythema Infectiosum (Slapped Cheek)
- Adult Polyarthropathy
- Transient Aplastic Crisis
- Transient Pancytopenia
- Red Cell Aplasia in Immunocompromised- Perinatal InfectionsO Diagnostic TestO Vaccines and Drugs* PneumoniaO BackgroundO Diagnostic TestsO Vaccines and Drugs* PolyomavirusesO BackgroundO Diagnostic TestsO Vaccines and Drugs* SalmonellosisO BackgroundO Diagnostic TestsO Vaccines and Drugs* ShigellosisO BackgroundO Diagnostic TestsO Vaccines and Drugs* StreptococciO BackgroundO Diagnostic TestsO Vaccines and Drugs- Group A Streptococci- Group B Streptococci* ToxoplasmosisO BackgroundO Diagnostic TestsO Vaccines and Drugs* TuberculosisO BackgroundO Diagnostic Tests- Microscopic Characteristics- Cultural Characteristics- Skin Tests- MDRTBO Vaccines and Drugs
* West Nile Virus
O Background
- Clinical Syndromes
O Diagnostic Tests
O Vaccines and Drugs
* Yersinia
O Background
O Diagnostic Tests
O Vaccines and Drugs
3. Antibiotic Susceptibility
List of TablesAIDS NAT and other Direct
Identification Tests
Table 2: Major Companies Developing or Marketing
Adenovirus NAT and other
Direct Identification Tests
Table 3: Major Companies Developing or Marketing
Campylobacter NAT and
Other Direct Identification Tests
Table 4: Major Companies Developing or Marketing
Chlamydia NAT and other
Direct Identification Tests
Table 5: Major Companies Developing or Marketing
CMV NAT and other Direct
Identification Tests
Table 6: Major Companies Developing or Marketing
EBV NAT and other Direct
Identification Tests
Table 7: Major Companies Developing or Marketing
Gonorrhea NAT and other
Direct Identification Tests
Table 8: Major Companies Developing or Marketing
Hepatitis NAT and other
Direct Identification Tests
Table 9: Major Companies Developing or Marketing
Herpes NAT and other
Direct Identification Tests
Table 10: Major Companies Developing or Marketing
Legionella NAT and other
Direct Identification Tests
List of Tables (continued)
Table 11: Major Companies Developing or Marketing
Lyme Disease NAT
And Other Direct Identification Tests
Table 12: Major Companies Developing or Marketing
Mycoplasma NAT
And other Direct Identification Tests
Table 13: Major Companies Developing or Marketing
Papilloma Virus NAT
And Other Direct Identification Tests
Table 14: Major Companies Developing or Marketing
Pneumonia NAT
And other Direct Identification Tests
Table 15: Major Companies Developing or Marketing
Salmonella NAT
And other Direct Identification Tests
Table 16: Major Companies Developing or Marketing
Shigella NAT
And other Direct Identification Tests
Table 17: Major Companies Developing or Marketing
Streptococci NAT
And Other Direct Identification Tests
Table 18: Major Companies Developing or Marketing
Toxoplasmosis NAT
And Other Direct Identification Tests
Table 19: Major Companies Developing or Marketing
Tuberculosis NAT
And Other Direct Identification Tests
To order this report:: Future Infectious Disease Nucleic Acid TestingMore
Market Research ReportCheck our
Industry Analysis and InsightsNicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article